title: [Novel insulins].
abstract: Novel insulins have entered the market during recent years. The ultra-long acting insulins, insulin degludek and insulin glargine, the latter having a strength of 300 U/ml, exhibit a steady and predictable action curve. Studies have indicated that significantly fewer hypoglycemiae occur when using degludek in patients with either type 1 or type 2 diabetes, whereas similar evidence about glargine (300 U/mI) has been obtained in the treatment of type 2 diabetes. The long duration of action of both insulins brings long-needed flexibility to.their dosing.
authors.forename: Johan G
authors.initials: JG
authors.lastname: Eriksson
authors.forename: Merja K
authors.initials: MK
authors.lastname: Laine
mesh_terms: D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D000069036:Insulin Glargine / Q000494:pharmacology; D049528:Insulin, Long-Acting / Q000494:pharmacology; D061385:Insulins / Q000494:pharmacology*
chemical_list: D049528:Insulin, Long-Acting; D061385:Insulins; D000069036:Insulin Glargine; C571886:insulin degludec